SEC Form 4 · accession 0001104659-15-043013
AGILE THERAPEUTICS INC · AGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Altomari
Officer — Chief Executive Officer · Director
Period of report
Jun 2, 2015
Accepted (ET)
Jun 3, 2015 · 9:02 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261249
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2015 | P | 2,500 | $8.73 | A | 78,254 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $8.725 to $8.726, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.